Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
CRISPR Therapeutics Stock Surged Today: Is It a Buy?
05:31pm, Tuesday, 08'th Mar 2022
Recent comments from the company's CEO are prompting bullish momentum for the stock.
Why CRISPR Therapeutics Stock Is Soaring Today
04:18pm, Tuesday, 08'th Mar 2022
Despite big gains today, the biotech specialist's share price is still down roughly 46% over the past year of trading.
CRISPR Therapeutics' (CRSP) CEO Sam Kulkarni on Cowen 42nd Annual Health Care Conference (Transcript)
03:27pm, Monday, 07'th Mar 2022
CRISPR Therapeutics' (CRSP) CEO Sam Kulkarni on Cowen 42nd Annual Health Care Conference (Transcript)
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
10:50pm, Friday, 04'th Mar 2022 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.19, moving -1.85% from the previous trading session.
Can Biotech Stocks Provide Crypto-Like Growth for Your Portfolio?
11:15am, Thursday, 03'rd Mar 2022 The Motley Fool
Sometimes yes, but the risks are similar in magnitude too.
CRISPR Therapeutics - Progress Adds More Value Than Patent Setback Subtracts
10:53am, Thursday, 03'rd Mar 2022
CRISPR Therapeutics' share price has fallen by half across the past 12 months - although the company is making solid progress and may soon win approval in Sickle Cell Disease.
2 Stocks to Buy No Matter What Happens in March
03:45pm, Tuesday, 01'st Mar 2022 The Motley Fool
Keep your eyes on the prize.
Patent Ruling Is a Setback for Gene-Editing Firms Tied to Crispr Nobelists
01:55pm, Tuesday, 01'st Mar 2022 Barron''s
The decision is a setback for Intellia Therapeutics, Crispr Therapeutics, and Caribou Biosciences, and a win for Editas Medicine and Beam Therapeutics.
Should You Buy Stocks Now? Here's What Warren Buffett Thinks
10:52am, Tuesday, 01'st Mar 2022 The Motley Fool
Buffett's latest letter to Berkshire Hathaway shareholders revealed the legendary investor's present mindset.
Peloton Isn't the ONLY Takeover Target. What Companies Could Be Bought Out in 2022?
03:07pm, Wednesday, 23'rd Feb 2022
Savvy investors can generate lucrative returns by investing in companies that look like prime takeover targets. This article speculates on a number of takeover targets of 2022.
Why Jim Cramer Believes Sirius XM Is Inexpensive
12:32pm, Wednesday, 23'rd Feb 2022 Benzinga
On CNBCs "Mad Money Lightning Round," Jim Cramer said CRISPR Therapeutics AG (NASDAQ: CRSP ) is likely to "lose a lot of money. But more importantly, this is the kind of company right now that is so out of favor that, unless you are willing to take a beating, which I do not encourage, I think you have to take a pass on it," With American Airlines Group Full story available on Benzinga.com
CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y
04:48pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.
CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y
01:09pm, Wednesday, 16'th Feb 2022
CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.
3 Biotech Stocks to Buy in February
10:56am, Wednesday, 16'th Feb 2022 The Motley Fool
Their long-term prospects appear to be bright.
CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Tops Revenue Estimates
10:25pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) delivered earnings and revenue surprises of -5.75% and 139.40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st
